Period 2 efficacy
HO lesions
SECONDARY
Based on the outcomes of period 1, the prespecified primary end point for efficacy for period 2 was prospectively changed to the number of new lesions in patients crossing over from placebo to garetosmab as assessed by CT. Additionally, we assessed efficacy at week 56 relative to week 28 in total volume of new HO lesions by CT, the number of new lesions by PET, TLA by PET in new HO lesions and percent of patients with new lesions by CT and PET. A full list of secondary and exploratory end points is provided in Supplementary Table 